Amgen and Gilead deliver lacklustre early clinical results with AMG 355 and denikitug respectively.
ApexOnco Front Page
Recent articles
Lilly makes its second in vivo Car-T acquisition, buying the privately held Kelonia for $3.25bn.
The company reports an “unprecedented” 100% PSA50 rate with JANX007, but in a small, selected number of patients.
Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.
Myelofibrosis projects and Merck's ROR1 ADC fight for attention at this month's conference.
Party season approaches; but first, conferences.
Two cast-offs comprise the private group's attempts to hit PARP1 and PARP7.
A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders.
